D.C. Circuit Hears Challenge to DEA Cannabis Scheduling Authority

Constitutional Challenge Reaches Appellate Court

MMJ International Holdings presented oral arguments before a three-judge D.C. Circuit panel, asserting that the DEA's continued Schedule I classification of cannabis violates separation-of-powers principles outlined in recent legal scholarship. The petitioner's brief referenced a Yale Law Journal article analyzing the erosion of legislative control over drug scheduling since the Controlled Substances Act's passage in 1970. It's the first time an appellate court has been asked to rule directly on whether the DEA's scheduling authority constitutes an unconstitutional delegation of legislative power in the cannabis context.

Counsel for MMJ International said Congress delegated scheduling decisions to the DEA without establishing intelligible principles to guide executive discretion. The Yale Law Journal article cited in the brief documented how the DEA has rescheduled substances 83 times since 1971, with minimal judicial oversight and no requirement for legislative ratification. Cannabis has remained Schedule I for 56 years. Yet 38 states now authorize medical use and 24 permit adult recreational sales.

Yale Law Journal Analysis Frames Legal Theory

The petitioner's argument relies on a 2024 Yale Law Journal article titled "The Collapse of Delegated Drug Scheduling," which traced how executive agencies expanded scheduling authority beyond Congress's original intent. Professor Elena Vasquez of Georgetown Law, the article's author, documented that the Controlled Substances Act's five-factor test for scheduling—abuse potential, scientific evidence, public health risk, psychopharmacological effect, and international treaty obligations—grants the DEA near-plenary discretion without meaningful statutory constraints.

The brief says this unbounded delegation allows the executive branch to criminalize conduct and restrict commerce without the political accountability that legislative action requires.

MMJ International's standing comes from its operation of licensed cultivation facilities in Nevada and Michigan. Schedule I classification bars interstate commerce, the company says. It prevents banking access. And it imposes effective tax rates exceeding 70 percent under Internal Revenue Code Section 280E. The brief calculates that rescheduling to Schedule III would reduce the company's federal tax liability by $4.2 million annually across its two-state footprint.

Government Defends Chevron Deference Framework

The Justice Department's answering brief defended the DEA's authority under the Administrative Procedure Act and the Chevron deference doctrine, saying courts have consistently upheld agency scheduling decisions since 1970. Deputy Assistant Attorney General Marcus Chen told the panel that Congress explicitly tasked the Attorney General—who delegated authority to the DEA—with scheduling determinations, and that the five-factor test provides sufficient guidance to satisfy nondelegation principles established in Gundy v. United States (2019).

The government's brief cited 14 prior circuit court decisions rejecting constitutional challenges to DEA scheduling actions, including the D.C. Circuit's 1994 ruling in Alliance for Cannabis Therapeutics v. DEA. Chen said MMJ International's separation-of-powers claim asks the court to second-guess scientific judgments within the DEA's expertise, a request foreclosed by Chevron U.S.A., Inc. v. Natural Resources Defense Council (1984). The Justice Department noted that the DEA initiated a notice-and-comment rulemaking in May 2024 to consider rescheduling cannabis to Schedule III, a process still pending as of July 2026.

Oral Argument Signals Judicial Skepticism

Judge Patricia Millett questioned whether the petitioner's remedy—striking down the scheduling statute—would create regulatory chaos by removing all federal controls on cannabis and other controlled substances. MMJ International's counsel responded that the court could issue a narrower ruling invalidating only the cannabis Schedule I designation, leaving the remainder of the Controlled Substances Act intact. Judge Millett pressed whether such relief would constitute judicial legislation, given that Congress has repeatedly declined to pass bills removing cannabis from Schedule I despite dozens of proposals since 2013.

Judge Neomi Rao, a Trump appointee, expressed interest in the Yale Law Journal's historical analysis. She asked the government whether the DEA's 83 rescheduling actions over five decades suggested that Congress had effectively ceded its legislative role. Chen replied that the volume of agency action reflects scientific progress, not constitutional overreach, and that Congress retains authority to amend the Controlled Substances Act at any time. The third panelist, Judge Robert Wilkins, didn't telegraph a position during the 47-minute argument.

A ruling is expected within six to nine months. For full background on this litigation and the DEA's pending rescheduling process, see the CannIntel topic hub on DEA scheduling and separation of powers.

The case is MMJ International Holdings, Inc. v. Drug Enforcement Administration, No. 25-1293 (D.C. Cir.). If the D.C. Circuit rules for MMJ International, the Justice Department is expected to seek en banc review or petition the Supreme Court. A petitioner victory wouldn't automatically deschedule cannabis but could force Congress to enact new legislation establishing clearer statutory standards for controlled-substance classification.